ACSL4 and hepatocellular carcinoma: When ACSL4 was knocked down or rosiglitazone (RTZ, ACLS4 inhibitor) was added, the OCR of the HK2‐overexpressing HCC cells was significantly decreased (Figure 4g,h and Figure S4e,f, Supporting Information).